Safety and Immunogenicity of MCV4 in HIV-Infected Youth

Phase 2, randomised, open-label trial of meningococcal A conjugate vaccine in meningococcal infection (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Immunogenic Responders, With Response Defined as a 4-fold or Greater Increase in Serum Bactericidal Antibody Titers From Study Entry to Week 28 After 2 Doses of MCV-4, Number of Participants With Short-term Immunogenicity, Defined as Number of Seroconverters at Week 4 and 8 more. Started Jun 2007; status: completed.